AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 157 filers reported holding AKERO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,184,804 | -7.6% | 43,195 | -14.7% | 0.00% | 0.0% |
Q2 2023 | $2,363,402 | +120.0% | 50,619 | +80.3% | 0.00% | +100.0% |
Q1 2023 | $1,074,379 | -26.4% | 28,081 | +5.4% | 0.00% | -50.0% |
Q4 2022 | $1,459,817 | +231.0% | 26,639 | +105.3% | 0.00% | – |
Q3 2022 | $441,000 | +261.5% | 12,976 | +1.2% | 0.00% | – |
Q2 2022 | $122,000 | -23.3% | 12,827 | +14.8% | 0.00% | – |
Q1 2022 | $159,000 | -30.6% | 11,178 | +3.1% | 0.00% | – |
Q4 2021 | $229,000 | -66.4% | 10,838 | -64.5% | 0.00% | – |
Q3 2021 | $682,000 | +166.4% | 30,572 | +195.8% | 0.00% | – |
Q2 2021 | $256,000 | -21.5% | 10,337 | -7.8% | 0.00% | – |
Q1 2021 | $326,000 | -55.6% | 11,215 | -60.7% | 0.00% | – |
Q4 2020 | $735,000 | +141.8% | 28,503 | +188.5% | 0.00% | – |
Q3 2020 | $304,000 | – | 9,879 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |